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Abstract
Functional magnetic resonance imaging (fMRI) is an extensively used method for the investigation of normal and path-
ological brain function. In particular, fMRI has been used to characterize spatiotemporal hemodynamic response to
pharmacological challenges as a non-invasive readout of neuronal activity. However, the mechanisms underlying regional
signal changes are yet unclear. In this study, we use a meta-analytic approach to converge data from microdialysis
experiments with relative cerebral blood volume (rCBV) changes following acute administration of neuropsychiatric
drugs in adult male rats. At whole-brain level, the functional response patterns show very weak correlation with
neurochemical alterations, while for numerous brain areas a strong positive correlation with noradrenaline release
exists. At a local scale of individual brain regions, the rCBV response to neurotransmitters is anatomically heteroge-
neous and, importantly, based on a complex interplay of different neurotransmitters that often exert opposing effects,
thus providing a mechanism for regulating and fine tuning hemodynamic responses in specific regions.
Keywords
Pharmacological MRI, microdialysis, meta-analysis, rat brain
Received 2 October 2019; Revised 26 February 2020; Accepted 4 March 2020
Introduction
Functional magnetic resonance imaging (MRI) is a
commonly used non-invasive technology that allows
mapping of brain activity at rest1 or in response
to specific sensory stimuli, cognitive tasks2 or neuro-
modulatory and neurovascular activity induced by
pharmacological agents;3–9 all by measuring spatiotem-
poral changes in blood flow, volume or blood oxygen-
ation. In so-called pharmacological MRI (phMRI)
experiments, acute administration of drugs induces
local or global hemodynamic responses that can be
detected with methods sensitive to different types
of magnetization-relaxation processes yielding func-
tional signals. While such functional MRI-signals
(fMRI) can be causally linked to various types of neu-
ronal and glial, e.g. astrocytic, activity,10–12 the actual,
condition-specific neurochemical processes underlying
the related phMRI signal changes remain elusive.
Until now, two main strategies have been commonly
pursued for gaining insights into the neurovascular
mechanisms underlying phMRI responses. First,
the dynamics of signals measured with different
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MRI methodologies were examined following local or
systemic injection of various agonists and antagonists
of neurotransmitters and neuromodulators;13–21
and second, phMRI experiments were combined with
concurrent microdialysis,7,21 aiming to fathoming into
the correlations between changes in neurotransmitter
concentrations and the magnitude of alterations
in cerebral blood circulation. Such studies reported
similar time courses for changes in the functional
signal and the substance-concentration measured by
microdialysis.7 Yet microdialysis has limited spatial
and temporal resolution, and most importantly, assess-
ment of brain-wide neurochemical dynamics by means
of such a minimally invasive method remains practical-
ly impossible.
In the present study, we report an alternative
method that overcomes the latter problem by means
of a mathematical-statistical, meta-analysis strategy.
Specifically, while individual microdialysis experiments
are restricted to measurements in single brain regions
of interest (ROI), the number of studies, and thus the
number of examined ROI, is vast. Therefore, micro-
dialysis sessions collectively, if properly normalized,
can converge into a whole-brain neurochemical map22
consistent with fMRI measurements. The aim of
the present study has therefore been to achieve a
data-convergence, by normalizing, summarizing and
integrating phMRI and microdialysis data published
studies in adult rats (Figure 1). Our analysis was con-
ducted on phMRI and microdialysis time-series of
brain response patterns to a selection of systemically
administered neuropsychiatric drugs (amphetamine,
apomorphine, cocaine, fluoxetine, nicotine, phencycli-
dine (PCP) and yohimbine). Our selection was
prompted by the fact that these drugs represent differ-
ent molecular modes of action, e.g. interactions with
dopamine, acetylcholine, serotonin, noradrenaline,
and glutamate systems, as well as discrete therapeutic/
Figure 1. Schematic illustration of the convergence of spatiotemporal rCBV maps and microdialysis time-series to correlation
matrices. In the first step, time-series for each observable type, namely phMRI and neurochemical data, are extracted from published
studies. Each phMRI experiment provides rCBV time-series for 39 cortical and subcortical brain regions for baseline and post-
injection phase. In turn, each in vivo microdialysis experiment provides trajectories of basal and drug-induced changes of neuro-
transmitter concentrations in only one brain region. As previously reported, measurements in up to 117 brain regions can be
obtained. In order to reduce the data complexity and dimension, only the peak response and the time to peak from microdialysis
experiments are extracted and converted into matrices for each transmitter with rows representing the brain regions and columns
representing the drugs. In analogy, the peaks response and time were extracted from rCBV time-series. Subsequently, for rCBV
experiments, the brain-wide response pattern to each drug is expressed by a normalized vector such that each component denotes
the peak hemodynamic response in one brain region. Collectively, these vectors form a matrix that contains information on all drugs.
The neurochemical brain-wide response pattern to each drug is expressed by a symmetric matrix with components denoting the
response of a specific neurotransmitter within a specific brain region. In contrast to rCBV matrices that contain data from one
experiment, the neurochemical matrices contain meta-analysed data of numerous microdialysis experiments. In the final step, a
vector-matrix correlation analysis converges all data into information on similarity and differences of the two observable types.
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behavioral effects. Thereby, time-series of relative cere-
bral blood volume (rCBV) and the temporal profile of
extracellular neurotransmitter concentrations with com-
parable sampling rates were extracted from published
studies and transformed into multidimensional whole-
brain response patterns, expressed by matrices of differ-
ent size. Since microdialysis experiments often only pro-
vide data on changes of a limited number of transmitters
in one brain region, an extensive meta-analysis was con-
ducted to construct the whole-brain response matrix for
each neurochemical system. By focusing on normalized
peak response to drugs and a ROI-based averaging, we
reduced data complexity and dimension. Subsequently,
we developed and applied a meta-analysis-based
approach, which enables us to calculate Pearson corre-
lations of drug-induced peak hemodynamic response
and peak neurotransmitter concentration changes at
whole-brain level.
While numerous methods for analyzing the correla-
tion of time-series of consistent sampling rate exist,
analysis of datasets with differing spatiotemporal
scale is a challenging problem, for which a generalized
mathematical scheme is developed in this study. In
addition, the influence of different variables, parame-
ters and individual studies on overall findings was
assessed by sensitivity analyses and demonstrates the
robustness of the results.
Due to the spatial, morphological heterogeneity of
the brain, different brain regions are likely to have dis-
tinct neurochemical underpinning of phMRI signals.23
To investigate whether and to what degree similarities
and differences at ROI-level influence the whole-brain
statistics and observations, we conducted secondary
correlation and cluster analyses on a representative
set (caudate putamen, globus pallidus, hippocampus,
hypothalamus, nucleus accumbens, prefrontal cortex,
septum and raphe nuclei) of cortical and subcortical
brain areas. These brain regions play key roles within
the mood, reward, and addiction neurocircuitries,24
which are known to be affected by the drugs under
investigation in this study, particularly psychostimu-
lants, antidepressants. Therefore, understanding the
relationship between neurochemical and functional sig-
nals within these regions will not only improve our
understanding of the hemodynamic response but may
generate new hypotheses on the complex chemical
interactions within brain networks.
Methods
Neurochemical dataset
As reported in our previous studies,22,25–28 drug-
induced alterations in extracellular neurotransmitter
concentrations as measured by in vivo microdialysis
experiments in rats were extracted systematically and
meta-analyzed to estimate averaged, normalized (i.e.
baseline levels set to 100%) neurochemical response
profiles. The matrices were obtained from Syphad
database (www.syphad.com)22 for amphetamine, apo-
morphine, cocaine, fluoxetine, and nicotine. In analogy
to data mining and integration steps of Syphad, the
online portal of the National Library of Medicine
(http://www.ncbi.nlm.nih.gov/pubmed/) including
PubMed, PubMed Central and MEDLINE was used
as the platform for literature research for phencyclidine
and yohimbine. A systematic screening of the original
research articles published until 01.01.2019 was per-
formed based on the keywords rat (AND) microdialy-
sis (AND) (brain region (OR) neurotransmitter (OR)
metabolite (OR) neuropeptide) (AND) (phencyclidine
(OR) PCP (OR) yohimbine). The keyword neurotrans-
mitter is a general representative in the search string
which was replaced by the actual name and/or
abbreviation of transmitters and metabolites (e.g.
dopamine, glutamate, homovanilic acid/HVA, etc.).
In addition, the reference sections of identified papers
as well as review and meta-analysis articles were then
screened for further relevant citations. Only peer-
reviewed original research articles in English language
were chosen for data mining if they provided the
absolute or relative change in neurotransmitter or
metabolite concentrations within a brain region either
numerically or in graphical manner. We excluded
articles using animals other than rats. All selected stud-
ies were performed in outbred rats with no specific
genotype or phenotype or provided data for a wild-
type control group were included. Furthermore,
animals did not receive any behavioral training prior
to drug treatments. Abstracts and unpublished studies
were not included.
In general, each microdialysis experiment provides
time-series of basal concentration and drug-induced
changes (in minute scale) for a limited number of neu-
rotransmitters and metabolites within one brain region.
These time-series are presented often as figures in the
literature. Since microdialysis experiments are often
conducted with different sampling rates, we only
extract the peak response (xi) of a transmitter to the
drug normalized to its baseline value and the time of
the peak. In our previous studies,22,25–28 we conducted
fixed-effect meta-analyses since the choice of fixed vs.
random effect models depends strongly on the hypoth-
esis as well as the extent of heterogeneity. In particular,
if all included studies included in the analysis are
reporting an estimate of the same effect and our goal
is to calculate the overall effect size for the identified
population without generalization to other popula-
tions, then a fixed effect model is more appropriate.29,30
In the present study, we compute random effect
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weighted averages for subgroups with minimized
level of heterogeneity in experimental design, e.g.
meta-analysis of the changes in a particular neurotrans-
mitter such as glutamate in a specific brain region
such as prefrontal cortex following a specific dosage
of a drug. Due to the skewness of experimental designs
towards male, adult, Sprague-Dawley rats, the
expected level of heterogeneity is low. Nevertheless,
the statistical heterogeneity can influence the findings
and reduce our ability to draw robust overall conclu-
sions. Thus, we calculated I2 which describes the
proportion of total variation in study estimates due
to heterogeneity,31 s2 which denotes between-study
heterogeneity and then calculated random-effect
meta-analyses by integrating s2 into the weights.
To this end, we first calculated the weighted (using
precisions wi as weights) fixed effect average of study
estimates X¼Pwixi/
P
wi, as introduced by Higgins
and Thompson.31 We then conduct the Cochran
Q-test of homogeneity, Q¼Pwi(xi-X).2 A moment-
based estimate for s2 is then given as s2¼ (Q-df)/
(
P
wi-(
P
wi
2
=
P
wi)), where df denotes degrees of free-
dom. Furthermore, I2 statistics is calculated by
I2¼ ((Q-df)/Q)100%. While thresholds for the inter-
pretation of I2 can be inaccurate, we follow Cochrane
Handbook for Systematic Reviews of Interventions
(https://handbook-5-1.cochrane.org/) and consider
I2<40% as less important. The random effect weighted
average is obtained by adding the between-study
heterogeneity into the weights. Therefore, if s2r2
(variance of the study), then fixed and random effect
models yield the same results, meaning that heteroge-
neity between studies does not affect the findings.
This approach was further used to compute weighted
averages of peak times (ti). Since the meta-analyses
refer to different regions of interest, one may assume
that the ROIs are provided (or nested) within studies,
so that a hierarchical meta-analysis model would be
more appropriate. However, less than 5% of all micro-
dialysis studies provide information on several ROIs in
a single report. Therefore, a hierarchical analysis was
not applied.
Calculations were conducted in MATLAB R2015a.
Results did not differ from estimates provided by meta-
for package in R.32 Codes, extracted data and results
of random-effect meta-analyses and heterogeneity
analyses are provided on the Center for Open Science
platform (https://osf.io/zj6ae/).
With respect to concentration changes, the neuro-
chemical matrix contains in each entry an average of
normalized peak response of a particular neurotrans-
mitter within a specific brain region. Thereby, amino
acids, monoamines and their direct metabolites repre-
sent 95.2% of all matrix entries. Consequently, no
statistically reliable conclusions can be made for
other transmitter systems. Thus, the analysis was
focused on response profiles of acetylcholine (ACh),
dopamine (DA), c-aminobutyric acid (GABA), gluta-
mate (Glu), noradrenaline (NA), and serotonin (5-HT).
Neurochemical response profiles
For each drug-dose combination, the response profile
was presented as a numerical matrix with rows denot-
ing the measured changes in neurotransmitter concen-
tration and the columns presented brain areas within
the neurochemical connectome of rat brain.33 In order
to represent the data intuitively, i.e. decrease in concen-
tration as a loss and increase as a gain in neurotrans-
mitter concentration, data were converted by
subtracting 100% from all data points. In other
words, the drug effect on brain neurochemistry is
reflected in the sign of the matrix components. As
drugs were administered in different doses, numerous
(k) matrices (Rij)
k per drug exist, whose elements refer
to the change of a transmitter i, in brain region j.
Since, the matrices (Rij)
k contain the outcome of
meta-analyses, i.e. average values of numerous micro-
dialysis experiments, the maximum peak does not
relate to outliers but to largest average values. To this
end, we constructed a matrix M, such that each of
its elements Mij¼maxk(Rij)k if (Rij)k>0 and Mij¼
mink(Rij)
k if (Rij)
k<0. An exploration of the temporal
dynamics of drug-induced alterations of extracellular
neurotransmitter dynamics as a function of drug dose
(Supplementary Information, Table S1) outlines con-
siderable differences between the both time-course of
response and dose conditions across the assays for each
compound. Therefore, a dynamical convergence of the
matrices is not feasible.
The different spatial resolution of MRI and micro-
dialysis experiments poses a further problem, as the
anatomical ontologies are inconsistent. To overcome
this issue, we converge the terminology of neurochem-
ical connectome of rat brain33 and stereotaxic MRI
template19 into a coarse-grained ontological frame-
work analogous (Supplementary Information, Table
S2) to our previous studies.34 The use of this ontology
results in multiple cases of many-to-one mappings, for
example, subregions of the ‘lateral hypothalamus’ and
‘medial hypothalamus’ are assigned to the (coarser)
label of ‘hypothalamus’. In order to resolve this issue,
a weighted ROI-average of neurotransmitter changes
within all sub-regions was calculated using the numpy
(https://numpy.org/) function ‘np.average’ in python,
with the ‘weights’ parameter set to the number of
rats. It is noteworthy that the heterogeneity in the
cytoarchitecture often indicates that an averaging with-
out considering anatomical properties is not optimal.
However, the comparably small standard deviation of
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the matrix entries among sub-regions suggests that,
from statistical point of view, the sub-region specific
differences are negligible and averaging is admissible.
The resulting neurochemical response matrix
(Supplementary Information, Figure S1) outlines how
the seven drugs selected for this analysis comprise
diverse neurochemical response patterns. For example,
the prefrontal cortex and dopamine (CORTEX,
PREFRONTAL and DA in the figure) show a mixture
of both up or down response profiles across the six
compounds profiled within this region. This is an
intended consequence from the selection of diverse
compounds for this work, since this enables the corre-
lation of relative cerebral blood volume (rCBV) and
neurochemical response across a variety of compound
mechanism-of-actions (MOAs).
phMRI dataset
Functional magnetic resonance imaging techniques
enable the detection of hemodynamics (cerebral blood
flow (CBF), cerebral blood volume (CBV) or oxygen-
ation level of hemoglobin (BOLD)) response to
changes in the activity of neuronal populations in prox-
imity of blood vessels. For pharmacological stimuli,
previous studies35 have shown a spatiotemporal cou-
pling between the percent changes in CBV and
BOLD relaxation rates. Nonetheless, CBV shows a
higher contrast-to-noise ratio than BOLD, and was
used as the detection method underlying the data
used in this study. CBV experiments provide T2*- or
T2-weighted image time series of transient drug-
induced changes in blood volume with respect to a
local resting state blood volume obtained by a contrast
agent-enhanced relaxivity. The relative CBV (rCBV) is
then obtained from the measured signal S(t), the esti-
mated background signal in absence of the transient
functional stimuli (B(t)) and the signal intensity prior
to the administration of the contrast agent (Spre): rCBV
(t)¼ ln(S(t)/B(t))/ln(B(t)/Spre). The peak response for
different brain regions was extracted from the time-
course of rCBV(t) that were made available by
Angelo Bifone (IIT, Italy). The measurements have
been previously processed and reported for 1mg/kg
D-amphetamine (n¼ 17) i.v.,20 0.2mg/kg apomorphine
(n¼ 5) i.v.,19 0.5mg/kg cocaine (n¼ 8) i.v.,21 10mg/kg
fluoxetine (n¼ 7) i.p.,20 0.35mg/kg nicotine (n¼ 9)
i.v.,18 0.5mg/kg phencyclidine (n¼ 24) i.v.16 and
0.75mg/kg yohimbine (n¼ 6) i.v.17
All animals used in the experiments were male adult
Sprague-Dawley rats. Brain region designations were
defined by the stereotaxic MRI template set for the
rat brain19 and converged into the joint ontological
framework (Supplementary Information, Table S2) as
described above. Compound rCBV response was
averaged into one value for each brain in the case of
many-to-one ontology mappings (due to the nature of
going from high to lower resolution), resulting into
coarse-grained matrix for hemodynamic response
(Supplementary Information, Figure S2).
Neurochemical and MRI response profile correlation
analysis
Compound neurochemical response profiles for each
brain region-neurotransmitter pair as well as the corre-
sponding brain-region specific rCBV responses were
extracted. Pearson correlation was calculated between
the two numerical arrays by using the scipy (https://
www.scipy.org/) function scipy.stats.pearsonr in
python. The output of this calculation q is a real
number ranging from 1.0 (perfect negative correla-
tion, i.e. rCBV changes are opposite to neurochemical
alterations) to 1.0 (i.e. perfect correlation, where rCBV
changes respond in an identical way to alterations of
neurochemical levels). We consider q¼ 0 as no corre-
lation, 0<|q|<0.2 as very weak, 0.2|q|<0.4 as weak,
0.4|q|<0.6 as moderate, 0.6|q|<0.8 as strong, and
0.8|q|<1 as very strong correlation36 indicating the
strength of shared response between rCBV or neuro-
chemical spaces upon compound administration. While
confidence intervals of the correlations are provided,
we report all correlation values including the non-
significant relations as potential trends that may
require further investigation in future studies. No indi-
vidual study skewed the overall statistics; however, the
inclusion and exclusion of specific drugs and/or neuro-
transmitter systems may affect the final findings. Thus,
OFAT (one-factor-at-a-time) sensitivity analyses were
performed a posteriori to ensure the robustness of the
analysis results with respect to effect modifiers.
Bi-cluster analysis of correlation results across brain
region and neurotransmitters
Hierarchical bi-clustering of the correlation results was
performed using the matrix of Pearson correlation
values for the compounds across each neurotransmitter
and brain region tuple, using the Seaborn ‘clustermap’
function with the method set to ‘average’, and the
metric set to ‘Euclidean’.
Results
The keyword-based search of abstracts, titles, or both
identified 2449 publications. Out of these, 774 studies
were original research articles on in vivo microdialysis
in 22,489 rat brains and provided data for neurochem-
ical meta-analysis. The phMRI studies and the major-
ity microdialysis experiments were conducted in adult
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(89.1%), male (90.5%), Sprague-Dawley rats (67.9%),
while there were variations in other experimental
parameters used in microdialysis studies
(Supplementary Information, Figure S3). In contrast
to phMRI studies, 88.7% of microdialysis experiments
(n¼ 20,383) were conducted in awake, freely moving
animals. Thereby, the choice of anesthetic agents and
the applied concentrations varied notably
(Supplementary Information, Table S3). The heteroge-
neity analyses suggest that in 20% of cases the I2 was
larger than 40% and the fixed- and random effect
model results differed. Nevertheless, only 2.5% of
such cases were associated with potential effect modi-
fiers such as age, strain and use of anesthesia. For
instance, administration of 10mg/kg cocaine increased
dopamine concentration in adolescent animals by
306 3% and thus, significantly less (p< 0.05, one-
way ANOVA) than in adult rats (371 0.2%).
Heterogeneity tests further suggest that the applica-
tion of anesthesia affects the striatal dopaminergic
response to 10mg/kg of phencyclidine. While data
obtained from awake, freely moving animals suggest
study homogeneity (s2¼ 0.02; I2¼ 33%; random-
effect mean: 252% with 95% confidence interval:
[234, 270]), the application of anesthesia is associated
with significant (p< 0.00001) heterogeneity (s2¼ 0.27;
I2¼ 94%; random-effect mean: 232% with 95% confi-
dence interval: [173, 292]). Therefore, in spite of few
exceptions, the analyses reported in this study remain
largely robust with respect to experimental parameters.
Common features of neurochemical response
We extracted and conducted meta-analysis on percent-
age changes in neurotransmitter (i.e. acetylcholine
(ACh), 5-HT, dopamine (DA), GABA, glutamate
(Glu), and noradrenaline (NA)) concentrations relative
to basal levels within 18 cortical and subcortical brain
areas (amygdala, anterior cingulate cortex, bed nucleus
of stria terminalis, caudate putamen, frontal cortex,
globus pallidus, hippocampus, hypothalamus, nucleus
accumbens, prefrontal cortex, posterior cingulate
cortex, raphe, septum, substantia nigra, temporal
cortex, ventral pallidum, and ventral tegmental area).
The drugs under consideration were applied systemat-
ically in wide ranges of doses: amphetamine (0.2–
30mg/kg), apomorphine (0.1–3mg/kg), cocaine
(0.05–40mg/kg), fluoxetine (0.3–40mg/kg), nicotine
(0.05–135mg/kg), phencyclidine (0.3–20mg/kg) and
yohimbine (0.1–5mg/kg). The heterogeneity tests
of the in vivo microdialysis experiments suggest
that the study estimates are largely homogeneous
(median s2¼ 0.02; median I2¼ 27.61%). However,
18.3% of the cases showed considerable heterogeneity
(i.e. 75%<I2< 100%) that justifies the choice of
random-effect model for meta-analysis.
Thereby, the results suggest diverse dynamical pat-
terns for different neurotransmitter systems, which
show different levels of sensitivity to specific molecular
modes of action of the drugs. All drugs in all doses
increase 5-HT and ACh levels in all investigate brain
areas by approximately 247 30% and 188 11%.
However, apomorphine in the range of 0.3–3mg/kg
moderately reduced ACh levels in caudate putamen
from 10 to 25%. Moreover, apomorphine reduced
dopamine levels in caudate putamen, nucleus accum-
bens and prefrontal cortex by up to 73%. All other
drug-dose combinations increase dopamine levels nota-
bly in cortical and subcortical brain regions (in average
464 41%). GABA dynamics represents a non-linear
response pattern, that timing but not in magnitude, is
opposite to glutamatergic response. In particular, low
concentrations of nicotine and apomorphine reduce
GABA levels in subcortical structures such as hypo-
thalamus and ventral pallidum, and in prefrontal
cortex whereas phencyclidine and amphetamine and
higher concentrations of apomorphine enhance
GABA concentrations in globus pallidus (160%),
caudate putamen (187%), septum (210%), and pre-
frontal cortex ( 200%). Glutamate in turn is increased
by all drugs by approximately 77 14%, but 10mg/kg
of fluoxetine which reduces Glu levels in frontal cortex
by 40%. NA as well is enhanced by all drugs by in
average 245 76%.
Common features of hemodynamic response
As previously reported,3,6,16–20 hemodynamic response
to drug challenges was associated with selective activa-
tion of pathways based on their molecular modes of
action and in a dose-dependent manner. These findings
will be briefly summarized in the following. While
amphetamine induces an anatomically indistinctive
activation of the brain, the response to other drugs
including psychostimulants such as cocaine and phen-
cyclidine was specific. In particular, cocaine injection
leads to the significant activation of various cortical
(such as prefrontal, frontal, and cingulate) and subcor-
tical (caudate putamen, nucleus accumbens, and thala-
mus) areas that are associated with reward circuitry.
Significant positive rCBV changes (Z> 2.3 vs. vehicle,
cluster correction at p ¼ 0.05) induced by phencycli-
dine were observed in cortico-limbo-thalamic regions
(medial prefrontal, cingulate, orbito-frontal, and
retrosplenial cortices), with extension into the motor,
visual, parietal-, and temporal association and rhinal
cortices. Significant activation was further observed in
subcortical brain regions such as extended amygdala,
thalamus and postero-dorsal, antero-dorsal and ventral
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and posterior hippocampus. Fluoxetine, in turn, shows
a largely cortical effect as well as foci in the hippocam-
pus, ventral tegmental area and in the thalamus.20
Similarly, yohimbine administration leads to the
activations in several cortico-limbic areas (Z> 2.3,
pc<0.01) such as prefrontal, cingulate, orbito-frontal,
and retrosplenial cortex, with extension into the motor,
visual, parietal-, and temporal-association areas.
Moreover, in addition to extra-hypothalamic stress cir-
cuit (e.g. extended amygdala), hemodynamic response
in subcortical structures such as caudate putamen,
nucleus accumbens, ventromedial and dorsolateral
thalamus, and ventral hippocampal area was signifi-
cantly increased. The administration of either apomor-
phine or nicotine induces significant activation
in particularly strong effects in the orbitofrontal and
prefrontal cortices, in the insular cortex extending back
to the ectorhinal/perirhinal cortices and thalamus.
Nicotine further enhances rCBV in the amygdala,
ventrocaudal hippocampal structures, and nucleus
accumbens. Taken together, the overall phMRI find-
ings indicate largely overlapping cortical (prefrontal
cortex) and subcortical (Hippocampus, hypothalamus,
nucleus accumbens, septum, caudate putamen and ven-
tral tegmental area) hemodynamic response patterns
due to the action of these neuropsychiatric drugs
under investigation.
Correlation analyses
The analysis of similarities between hemodynamic
response and changes of neurotransmitter concentra-
tions induced by individual drugs at whole-brain level
suggest very strong correlations of 5-HT (q5-HT¼ 0.88)
and noradrenaline (qNA¼ 0.81) for nicotine, 5-HT
(q5-HT¼ 0.82) and GABA (qGABA¼0.99) for phency-
clidine and moderate negative correlations of ACh
(qACh¼0.48) and 5-HT (q5-HT¼0.43) for amphet-
amine. For other drugs, i.e. apomorphine, cocaine, flu-
oxetine and yohimbine, neurochemistry either very
weakly or weakly correlates with rCBV, and thus no
meaningful conclusion can be drawn.
In order to discover common principles, we calcu-
lated how neurochemical and functional response pat-
terns correlate for the set of all drugs. The analysis
suggests that changes in cerebral blood volume, while
relating to penetrating arteries and cortical layers,37
correlate only very weakly with changes in neurotrans-
mitter concentration as measured by microdialysis at
whole-brain level (qDA¼ 0.089, qGlu¼ 0.088, qNA¼
0.043, qGABA¼ 0.025, qACh¼ 0.010, q5-HT¼0.101).
Interestingly, the sensitivity analyses (Supplementary
Information, Tables S4 and S5) suggest that the exclu-
sion of each individual drug, but amphetamine,
does not alter the statistical findings. Excluding
amphetamine from the set of drugs leads to strong
positive correlations of hemodynamic response with
noradrenaline (qNA¼ 0.60), and strong negative corre-
lation with GABA (qGABA¼0.64). It is noteworthy
that amphetamine increases noradrenaline concentra-
tions and rCBV response in all brain regions, the
response magnitude at whole-brain level is negatively
correlated (qNA¼0.33), which may result into a
diminishing correlation of NA and hemodynamic
response due to an individual drug (Supplementary
Information, Table S6).
The lack of even moderate correlation of neuro-
transmitter and rCBV response to drugs at global,
whole-brain level may further be due to spatial hetero-
geneity in terms of differences in neurovasculature,
receptor distributions and cytoarchitecture of different
brain areas. To evaluate the impact of spatial structural
variability, we conducted a ROI-based correlation
analysis (Supplementary Information, Figures S4 and
S5). As previously reported,22 there is a general skew-
ness of microdialysis studies by means of an overem-
phasis on monoamine systems (particularly dopamine)
within the reward circuitry, which is also reflected in
the neurochemical database. The missing values related
to other neurotransmitter systems and brain regions do
not permit a complete correlation analysis for all
regions of interest. In other cases, if data were provided
for at least two of the seven drugs under consideration,
then Pearson correlations of neurochemical and rCBV
responses were calculated (Figure 2). While this strate-
gy allows us to conduct correlation analysis, the
obtained correlation values directly relate to the
number of drugs contributing to the calculation.
Thereby, smaller numbers of drugs generally lead to
higher magnitudes of correlations. Therefore, the find-
ings are presented as pairs of Pearson correlation in
brain region A for neurotransmitter B, qA
B, and
number of drugs included in the analysis m, to avoid
an over-interpretation of our findings (Supplementary
Information, Table S7). All brain areas but caudate
putamen show a positive correlation of noradrenaline
transmission and a negative correlation of glutamate
dynamics with hemodynamic response. In prefrontal
cortex, alterations in ACh and NA correlate perfectly
with changes in rCBV (qPFC
ACh¼qPFCACh¼ 1, m¼ 2),
dopamine correlates moderately (qPFC
DA¼ 0.57,
m¼ 4), whereas 5-HT and glutamate are negatively
correlated to hemodynamic response (qPFC
5-HT¼
0.27, m¼ 4; qPFCGlu¼0.86, m¼ 3). In hippocam-
pus, GABA and NA changes correlate positively with
functional response (qHC
GABA¼ 1, m¼ 2; qHCNA¼
0.46, m¼ 3), 5-HT and dopamine changes correlate
negatively with rCBV changes (qHC
5-HT¼0.29,
m¼ 3; qHCDA¼1, m¼ 2) and correlations between
changes in acetylcholine concentrations and rCBV are
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negligible (qHC
ACh¼0.007, m¼ 4). Dopamine
dynamics perfectly correlates positively and negatively
with hemodynamic response in globus pallidus, septum
and hypothalamus, respectively (qGP
DA¼ 1, m¼ 2;
qSeptum
DA¼ 1, m¼ 2; qHyTDA¼1, m¼ 2), while nor-
adrenaline changes in hypothalamus positively corre-
late with rCBV response (qHyT
NA¼ 1, m¼ 2). In
raphe, drug-induced alterations in 5-HT levels are
very strongly correlated to hemodynamic response
(qRaphe
5-HT¼ 0.85, m¼ 3). Dopamine and 5-HT con-
centrations in the ventral tegmental area correlate
with rCBV changes perfectly (qVTA
DA¼ 1, m¼ 2;
qVTA
5-HT¼ 1, m¼ 2), while glutamate system shows
the opposite behavior (qVTA
Glu¼1, m¼ 2). A similar
behavior can be observed in nucleus accumbens, where
all transmitters but glutamate are positively correlated
to changes in hemodynamic response (qAcb
ACh¼ 1,
m¼ 2; qAcbNA¼ 0.59, m¼ 3; qAcbDA¼ 0.51, m¼ 6;
qAcb
5-HT¼ 0.51, m¼ 5; qAcbGlu¼0.33, m¼ 4). In
caudate putamen, all transmitter but noradrenaline
correlate positively with rCBV changes (qCPu
Glu¼ 1,
m¼ 2; qCPuACh¼ 0.89, m¼ 3; qCPuDA¼ 0.78, m¼ 6;
qCPu
GABA¼ 0.77, m¼ 3; qCPu5-HT¼ 0.29, m¼ 4;
qCPu
NA¼1, m¼ 2). It is noteworthy that m¼ 2 with-
out an exception leads to perfect positive and negative
correlation scores, indicating that it may not present an
appropriate choice for discovering true patterns.
In contrast, for m 3, correlation patterns emerge
that show robustness with respect to brain areas. In
average, drug-induced changes in glutamate levels
appear negatively correlated with rCBV, whereas nor-
adrenaline and dopamine systems are positively corre-
lated with relative cerebral blood volume alterations.
Thereby, 5-HT reveals a diverse response pattern,
as it positively correlates with hemodynamic response
in nucleus accumbens and raphe and negative correla-
tions in prefrontal cortex and hippocampus, which may
relate to serotoninergic projections in rat brain origi-
nating in raphe and strongly innervating nucleus
accumbens with a weaker outreach of cortical
regions.33 While the rough sampling times of micro-
dialysis experiments and differences in measurement
time-scales with phMRI experiments did not allow a
quantitative comparison of drug response trajectories,
we analyzed peak response times (Supplementary
Information, Table S8) to include the temporal dimen-
sion in our investigation. Thereby, the response time is
negatively (Supplementary Information, Figure S6),
yet not significantly (overall p¼ 0.57) correlated with
the hemodynamic response for most neurotransmitters.
In agreement with previous studies,38 glutamate
and GABA show an opposite dynamics, i.e. the
Pearson coefficients for glutamate and GABA are of
opposite sign.
Figure 2. Region of interest (ROI)-based Pearson correlation between drug-induced neurochemical and hemodynamic response
patterns shows an anatomical heterogeneity underlying the relationship between neurotransmitter concentrations and rCBV signal
changes. The complex and region-specific interplays of different neurotransmitter systems generate hypotheses on internal func-
tioning of different neurocircuitries in the brain. For instance, the push-pull action within VTA (positive for dopamine and 5-HT,
negative for glutamate) appears to play a role in the regulation of hemodynamic response and the functional control of reward
circuitry. Correlation values were calculated if data were provided for at least two of the seven drugs under consideration. Negative
and positive correlations are presented as shades of blue and red, respectively.
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Discussion
fMRI is widely used to study the operational organiza-
tion of the brain. The exact relationship between the
measured functional signal and the underlying neural
activity, however, remains unclear. Previous studies11
have examined the relationship between mesoscopic
electrical signals (e.g. various frequency ranges of the
mean extracellular field potential, often dubbed as
Local Field Potentials, LFP) and neurovascular activ-
ity patterns, such as those reflecting changes in blood
oxygenation. Extending this methodology by using
multishank and multisite electrodes can also provide
global neuronal and vascular activity patterns that
may help interpreting brain states. However, a concur-
rent widespread mapping of the regional neurochemi-
cal processes reflecting the activity patterns induced,
for example, by neuromodulators, is currently impos-
sible, despite of its utmost importance for drug design
and development. The gap is mainly due to the exper-
imental limitations of neurochemical measurement
techniques by biosensors or in vivo microdialysis.
While these methods allow the observation of drug-
induced alterations of extracellular neurotransmitter
concentrations at a small spatiotemporal scale, corre-
sponding to a small number of voxels in the usual
fMRI studies, simultaneous observation of drug effects
on the entire brain is not possible, as the minimally
invasive methods such as microdialysis – beyond their
limited spatiotemporal resolution – have also restricted
regional extent of sampling. Pharmacological MRI
(phMRI) could – in principle – overcome the latter
limitation, if local changes in the phMRI signals are
consistently related to the concentration changes of dif-
ferent neuromodulators or drugs quantified by means
of biosensors. In other words, a robust, potentially
causal relationship between chemicals and phMRI
signal changes, eventually permitting a linear (or
non-linear) estimation of an impulse response function
for various regions, which in turn allows the inverse
estimation of local neurochemical changes by measur-
ing the phMRI signal-changes could indeed permit
a reliable convergence of regional data. Targeted phar-
macological manipulation of neurotransmitter systems
and simultaneous measurement of hemodynamic
response has indeed already provided some insights
into the effect of drugs on neurovascular cou-
pling.3,5,6,13 Puzzling, however is the fact that the
changes in the fMRI signal are often induced by alter-
ations in numerous dynamically coupled neurotrans-
mitter systems that respond directly (by the drug
acting on various proteins with different affinity) or
indirectly (i.e. through network interactions) to the
administration of neuropsychiatric drugs. While such
sets of neurochemical systems are non-unique and may
differ among drugs, the conjunction set (i.e. the ensem-
ble of neurotransmitters associated with hemodynamic
response that react non-specifically to all drugs) is
unique and is critical to characterize the link between
neurochemical and functional dynamics.
Using a set of representative neuropsychiatric drugs,
we were indeed able to find the above-mentioned con-
junction set as a universal neurochemical underpinning
of hemodynamic response. Notably, our whole-brain
correlation analysis did not directly lead to the identi-
fication of sets of neurotransmitters associated with
functional signal changes. However, our sensitivity
analyses suggest that the null-result is mostly due to
two factors, namely the small number of drugs for
which data exists and large variance in how different
brain regions respond to drugs. Based on currently
existing data, the robust core of our findings suggests
a positive correlation of noradrenaline and a positive
correlation of glutamatergic dynamics with hemody-
namic response. This finding is in agreement with pre-
vious studies that have shown direct noradrenergic
input to cerebral penetrating arteries and intracortical
microvessels, indicating a direct role of noradrenaline
in blood–brain barrier and cerebral blood flow.39–41
Surprisingly, our analysis does not provide evidence
that the magnitude of glutamate changes is driving the
functional response (if anything, an anticorrelation was
found). However, in agreement with recent functional
magnetic resonance spectroscopy (fMRS)38 and com-
bined fMRI-MRS42 in humans, the time courses of
changes in glutamate and BOLD signals induced
by visual stimulation are positively correlated. Our
findings are further consistent with an opposite dynam-
ics of glutamate and GABA response to stimuli.38
In addition, a feasible and clear indication of the impli-
cation of the noradrenergic system is identified.
Both, glutamate and noradrenaline, are well-known
to play key roles in neurovascular coupling, for
instance via the regulation of astroglial function and
cerebral microvascular4,8,39,43–45 and thus, the intensity
of fMRI signals.
While inhibition of metabotropic glutamate receptor
generally blocks the vascular response, their activation
by agonists leads to enhancements of intracellular
Ca2þ concentration in astrocytes and consequently
vasodilation as induced by neuronal stimulation.45
Furthermore, simultaneous multimodal measurements
of neuronal activity and glutamate concentration in
thalamus indicate a positive correlation with functional
signals.46 However, the importance of astrocytes in reg-
ulation of cerebral blood flow remains unresolved.47,48
We speculate that our inability to discover a positive
correlation between the magnitude of glutamate-rCBV
correlations is due to two reasons. Glutamate is the
main excitatory neurotransmitter in the central nervous
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system that is metabolized and released by neurons and
also astrocytes.49–51 Thereby, the astrocytes not only
regulate the glutamate levels but the dynamics of this
process may prevent observation of refined glutamater-
gic oscillations. Therefore, the rough time-resolution of
microdialysis experiments (in minutes) leads to not
only sampling active glutamate molecules associated
with neurotransmission but also to an added concen-
tration of free glutamate by astrocytes. This, in
turn, affects the correlation analysis directly and may
overshadow actual links between changes in glutamate
concentration and hemodynamic response.
However, the sign of the correlation may also relate
to an anatomical gradient between cortical and subcor-
tical regions, as neural activity appears to positively
correlate with functional activity for cortical and neg-
atively for subcortical regions.52 Indeed, previous stud-
ies have shown a high level of anatomical heterogeneity
in neurovasculature,12,53,54 receptor distribution33 and
generally BOLD signal among different brain regions52
that may have led to positive correlations in some and
negative correlations in other brain areas and subse-
quently a net-zero (meaningless) correlation at whole-
brain level. Nonetheless, the findings are based entirely
on correlations without an exploration of confidence
intervals and statistical significance. With growing
number of experiments and data, the investigation
needs to be complemented by such analyses to ensure
robustness of the identified correlations.
Beyond the global observations, our ROI-based
analysis further suggests that the involvement of
neurotransmitter systems in hemodynamic response is
anatomically heterogeneous and that not a single neu-
rochemical mechanism but rather a complex interplay
of various transmitter systems contributes to neurovas-
cular coupling. The correlation of rCBV changes with
neurochemistry in the main source of dopaminergic
projections within the reward circuitry, namely ventral
tegmental area (VTA), is an example of this observa-
tion. Our findings suggest that a push-pull action
(positive for dopamine and 5-HT, negative for gluta-
mate) is responsible for the regulation of hemodynamic
response and the functional control of this important
brain region. Such complex and region-specific inter-
plays of different neurotransmitter systems can also be
used to improve our understanding and generate
hypotheses on internal functioning of different neuro-
circuitries in the brain. For instance, a plausible obser-
vation is that dopamine correlates positively with
rCBV within the mesolimbic system and exerts oppo-
site effects in other regions.
While our results are feasible in light of previous
experimental findings, our study and its conclusions
are intrinsically limited to the databases they rely on.
phMRI measurements provide global, whole-brain
observations; however, phMRI experiments have only
been conducted using a small set of neuropsychiatric
drugs. The opposite is true for microdialysis experi-
ments that provide data for at least 260 drugs,22
however often incomplete with respect to number of
measured brain regions and transmitter systems.
Furthermore, due to differences in time-scales of meas-
urements, the presented analysis is only based on peak
response (i.e. peak response magnitude and time) and
not on spatiotemporal trajectories, which may contain
critical information. In general, trajectories of dynam-
ical systems depend on initial values/conditions and a
proper analysis needs to take both the initial values and
temporal dynamics into consideration. For instance,
previous MRS investigations38 indicate that different
baseline conditions may explain diverging signal
changes of GABA and glutamate. In the included
microdialysis experiments, the animals were wild-type,
drug-naı¨ve and did not undergo any behavioral manip-
ulations (e.g. stress) prior to the measurements. Thus,
one can safely assume that the baseline conditions are
comparable. To our surprise, numerous studies do not
report the basal concentrations. For example, 10 out of
15 studies on Yohimbine and over 50% of studies on
PCP do not report basal values. Thus, if we set it as a
key feature of the analysis, then numerous studies
would have been excluded. In addition, it is noteworthy
that the quantity of analyte collected by microdialysis
(i.e. absolute concentration) often represents only a
fraction of the ‘true’ extracellular neurotransmitter
levels. Differences in concentrations of calcium (mM)
of perfusate, flow rate (ml/min) or membrane surface
area (often reported as membrane length (mm) and
membrane outer-diameter (mm)) affect the relative
recovery, i.e. the ratio between the actual extracellular
concentration of an analyte and its dialysate concen-
tration, significantly.55 To avoid this issue, a large
number of microdialysis studies on drug effects
normalize the drug-induced response to the basal
levels measured in the study and report exclusively
the normalized (% baseline) values. Since rCBV, as
well, represents a relative measure of drug response,
the comparison of the two variables is feasible.
A further limitation of our study is due to the fact
that phMRI experiments are conducted in anesthetized
animals, whereas the majority of microdialysis experi-
ments were performed in awake, freely moving rats.
While drug–drug interactions generally may influence
the findings in a critical manner, analysis of variance
of microdialysis data obtained from awake and anesthe-
tized rats for the drugs under consideration did not show
any significant differences between the groups. However,
the application of halothane may induce notable hetero-
geneity in measurements of striatal dopamine concentra-
tions following acute administration of cocaine.
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While halothane is not a commonly used anesthetic
agent in the context of functional neuroimaging, depend-
ing on the applied anesthesia, the outcome of phMRI
may vary. Therefore, a more accurate comparison of
phMRI and microdialysis experiments would benefit
from phMRI data obtained from awake animals.
Conclusions
Our findings suggest that the neurochemical basis of
changes in functional MRI signals most likely relates
to a dynamical interplay of glutamate and noradrener-
gic transmission in the brain. However, more phMRI
data on preferably awake animals are required to
detect the refined role of other transmitter systems
such as dopamine, 5-HT and GABA in regulating the
magnitude of functional signal changes.
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